News >

Expert Explains Expanding Post-Ibrutinib Options in CLL

Danielle Ternyila
Published: Thursday, May 23, 2019

Jacqueline C. Barrientos, MD, MS
Jacqueline C. Barrientos, MD, MS
The armamentarium for patients with chronic lymphocytic leukemia (CLL) who progress following ibrutinib (Imbruvica) is rapidly expanding with a batch of exciting agents, according to Jacqueline C. Barrientos, MD, MS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x